Ashland (NYSE: ASH) $US72.84
A solid +7% bounce in Ashland shares overnight after they delivered a good third-quarter result, with sales and earnings ahead of expectations and full-year guidance maintained.
Ashland Global Holdings Inc (ASH US)
ASH US$76.72
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 76.72
- Change
- ▼ -0.09 (-0.12)
- Bid / Ask
- 76.67 - 76.69
- Volume
- 274,933
- Turnover
- 7,909,187
- Open
- 77.33
- Day Range
- 76.29 - 77.46
- VWAP
- 76.89
- Prev Close
- 76.81
- Last Trade
- 11/11 7:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Basic Materials
- Shares Issued
- 45,805,711
- NTA/Share
- 13.72
- Last Dividend
- 0.42
- Dividend Ex Date
- 1 SEP 2026
- Dividend Pay Date
- 15 SEP 2026
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 1,824.00
- EBITDA
- -516.00
- Profit
- -845.00
- Earnings Per Share (EPS)
- -18.23
- Dividend Per Share (DPS)
- 1.44
- Yield %
- 2.18
- Market Cap
- 3,513.27
- Price to Earnings Ratio (P/E)
- 49.18
Estimates (USD) · FY2027
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
- Revenue
- —
- EBITDA
- —
- Profit
- —
- Earnings Per Share (EPS)
- 4.35
- Dividend Per Share (DPS)
- —
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Undervalued
- Economic Moat
- None
- Financial Health
- Moderate
- Uncertainty
- Low
Morningstar Quantitative Rating as of 6 NOV 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 73.82 Fair value 84.12 One-star price 95.85
Morningstar Quantitative Rating as of 6 NOV 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 84.12
- Price / Fair Value
- 0.91
- Valuation
- Undervalued
- Uncertainty
- Low
Morningstar Quantitative Rating as of 6 NOV 2026. The slider runs from the five-star price (73.82) to the one-star price (95.85).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 76.28 |
| Price - 12 month high | 78.00 |
| Price - 12 month low | 48.00 |
| Pricing date | 5 NOV 2026 |
| Volume - avg. trading volume for the last ten days | 0.55 |
| Market capitalization | 3,508.69 |
| 12 Month High price date | 7 AUG 2026 |
| 12 Month Low price date | 20 NOV 2025 |
| Volume - avg. trading volume for the last 3 months | 0.61 |
| Price - 1 Day % Change | -0.21% |
| Price - 13 week price percent change | 6.39% |
| Price - 26 week price percent change | 45.96% |
| Price - 5 Day % Change | 2.55% |
| Price - 52 week price percent change | 50.34% |
| Price - YTD price percent change | 28.96% |
| Price % Change Month To Date | 10.90% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | -17.740 |
| EPS excluding extraordinary items - trailing 12 month | 1.640 |
| EPS Normalized - most recent fiscal year | 2.280 |
| Revenue/share - most recent fiscal year | 39.652 |
| Revenue/share - trailing 12 month | 40.707 |
| Book value per share - most recent fiscal year | 41.391 |
| Book value per share - most recent quarter | 40.836 |
| Book value (tangible) per share - most recent fiscal year | 13.717 |
| Book value (tangible) per share - most recent quarter | 14.347 |
| Cash per share - most recent fiscal year | 4.674 |
| Cash per share - most recent quarter | 9.608 |
| Cash Flow per share - most recent fiscal year | 7.065 |
| Cash Flow per share - trailing 12 month | 6.276 |
| Dividend per share - most recent fiscal year | 1.440 |
| Dividends per share - trailing 12 month | 1.670 |
| EBITD per share - trailing 12 month | 8.243 |
| EPS Basic excluding extraordinary items - most recent fiscal year | -17.740 |
| EPS Basic excluding extraordinary items - trailing 12 month | 1.560 |
| EPS including extraordinary items - most recent fiscal year | -18.230 |
| EPS including extraordinary items - trailing 12 month | 1.050 |
| Free Cash Flow per share - trailing 12 month | 4.398 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | 140.35 |
| P/E Normalized, most recent fiscal year | 33.75 |
| Price to sales - most recent fiscal year | 1.89 |
| Price to Tangible Book - most fiscal year | 5.38 |
| Price to Free Cash Flow per Share - most recent fiscal year | 25.36 |
| Price to Cash Flow per share - trailing 12 month | 15.53 |
| Price to Book - most recent fiscal year | 1.90 |
| P/E excluding extraordinary items high, trailing 12 months | 140.35 |
| P/E excluding extraordinary items low, trailing 12 months | 41.53 |
| Net Debt, LFI | 1,036.00 |
| Net Debt, LFY | 1,275.00 |
| Dividend Yield - 5 Year Average | 1.75% |
| Dividend Yield - indicated annual dividend divided by closing price | 2.18% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 2.18% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | 227.00 |
| LT debt/equity - most recent fiscal year | 77.15% |
| Payout ratio - most recent fiscal year | -7.90% |
| Total debt/total equity - most recent fiscal year | 78.26% |
| LT debt/equity - most recent quarter | 77.97% |
| Total debt/total equity - most recent quarter | 78.93% |
| Free Cash Flow - trailing 12 month | 199.00 |
| Payout ratio - trailing 12 month | 18.86% |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 1,824.00 |
| Revenue - trailing 12 month | 1,842.00 |
| EBITD - most recent fiscal year | -516.00 |
| EBITD - trailing 12 month | 373.00 |
| Earnings before taxes - most recent fiscal year | -809.00 |
| Earnings before taxes - trailing 12 month | 125.00 |
| Net Income available to common - most recent fiscal year | -845.00 |
| Net Income available to common - trailing 12 months | 52.00 |
| Earnings before taxes Normalized - most recent fiscal year | 39.00 |
| Net Income Available to Common, Normalized - most recent fiscal year | 106.00 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 2.20 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | -45.07% |
| Net Profit Margin % - trailing 12 month | 4.07% |
| Operating margin - 1st historical fiscal year | 4.82% |
| Operating margin - trailing 12 month | 6.79% |
| Pretax margin - trailing 12 month | 6.79% |
| Pretax margin - 1st historical fiscal year | -44.35% |
| Operating Margin - 5 year average | 7.24% |
| Pretax Margin - 5 year average | -4.64% |
| Free Operating Cash Flow/Revenue, 5 Year Average | 9.92% |
| Free Operating Cash Flow/Revenue, TTM | 10.80% |
| Net Profit Margin - 5 year average | -2.44% |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | -16.22% |
| Return on average assets - trailing 12 month | 1.64% |
| Return on average equity - most recent fiscal year | -34.80% |
| Return on average equity - trailing 12 month | 3.99% |
| Return on average assets - 5 year average | -1.11% |
| Return on average equity - 5 year average | -2.72% |
| Net Income/employee - most recent fiscal year | -283,448.28 |
| Revenue/employee - most recent fiscal year | 628,965.52 |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | -1.98% |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | 8.90% |
| Revenue/share (5 yr growth) | 3.71% |
| Growth rate% - Revenue, 3 year | -8.63% |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | -3.62% |
| Capital Spending growth rate, 5 year | -5.92% |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (USD, millions except per share)
| Actuals | Estimates | |||||||
| 2025 | 2026 | 2027 | ||||||
| Estimate breakdown | ||||||||
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | SEP 21 | SEP 22 | SEP 23 | SEP 24 | SEP 25 |
| Fiscal year: | 2021 | 2022 | 2023 | 2024 | 2025 |
| Period length: | 12 months | 12 months | 12 months | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
Ashland Inc (NYSE: ASH) US$63.94
Ashland has had a difficult run over the past few years, so the recent share price strength on takeover speculation has been a welcome development for shareholders, including MM. While the stock has rallied sharply over the past few weeks, it still trades on 16x depressed earnings, suggesting the market remains sceptical of its ability to turn things around.
Ashland (NYSE:ASH) $49.15
Ashland’s quarterly update overnight was disappointing, with earnings per share coming in lower than expected and the company trimming FY26 guidance. Shares traded down ~13%.
Portfolio Amendments – International Equities Portfolio
We are making several changes to the International Equities Portfolio
Ashland Inc (ASH US) $US53.02
We’ve retained Ashland Inc on the Hitlist for the International Equities Portfolio, awaiting a catalyst to buy. Our last updated opinion was in December, yet the share price has remained under pressure since.
Ashland Global Holdings (ASH US) $US76.08
As major indices continue to track around all-time highs, we’re becoming more conscious of looking beyond the well-known names in the US market that have been primary drivers of the strength, into more industrially focused companies that will benefit from a broadening of the market rally.
Ashland Global Holdings (ASH US) $US83.32
We originally covered Ashland, US-listed additives company back in May (here) adding to our Hitlist for the International Equities Portfolio. It was trading at ~$US77 with an improving outlook which quickly got captured in the share price which ran up to $US100, without our participation. This week, they released mixed Q3 results and though they lowered their FY24 sales guidance. Most analysts lower earnings estimates as a result , and shares are back in the low 80’s.
Ashland (ASH US) US$78.34
Ricky Sandler, the CIO at New York-based hedge fund Eminence Capital, presented first at this week’s Sohn Hearts and Minds conference. The order in which the 11 fund managers present is decided by how well their stock picks have done from last year’s event, a great idea for accountability! So, while Ricky was first up having last year’s best bet, Jun Bei Lu from Tribecca was the last cab off the rank!
Action
Updated
30/07/2026
09:51
ASH US
Updated 30/07/2026 09:51
MM remains bullish on ASH US ~$US72
Updated
24/06/2026
09:43
ASH US
Updated 24/06/2026 09:43
MM remains long & bullish ASH US ~US$64
Updated
30/04/2026
10:28
ASH US
Updated 30/04/2026 10:28
MM remains positive on ASH despite lower guidance
Updated
06/02/2026
10:57
ASH US
Updated 06/02/2026 10:57
MM is buying ASH US in the International Equities Growth Portfolio, targeting a 4% weighting around $64
Updated
11/06/2025
10:06
ASH US
Updated 11/06/2025 10:06
MM is bullish ASH US ~US$50
Updated
11/12/2024
10:05
ASH US
Updated 11/12/2024 10:05
MM likes the risk/reward towards ASH US ~$76
Updated
14/08/2024
10:23
ASH US
Updated 14/08/2024 10:23
MM is bullish ASH US around $US80
Updated
22/11/2023
16:42
ASH US
Updated 22/11/2023 16:42
MM is adding ASH US to our Hitlist
Business Summary
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
